S&P 500

5.277,51

0,80%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Foghorn Therapeutics Inc (FHTX)
Foghorn Therapeutics Inc (FHTX) Notícias

FHTX

Foghorn Therapeutics (FHTX)

Foghorn Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:FHTX

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
28/05/2024	08:00	GlobeNewswire Inc.	Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June	NASDAQ:FHTX	Foghorn Therapeutics Inc
23/05/2024	08:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:FHTX	Foghorn Therapeutics Inc
22/05/2024	19:21	GlobeNewswire Inc.	Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline	NASDAQ:FHTX	Foghorn Therapeutics Inc
20/05/2024	17:31	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:FHTX	Foghorn Therapeutics Inc
06/05/2024	08:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:FHTX	Foghorn Therapeutics Inc
06/05/2024	08:03	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:FHTX	Foghorn Therapeutics Inc
07/03/2024	09:09	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:FHTX	Foghorn Therapeutics Inc
25/01/2024	18:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FHTX	Foghorn Therapeutics Inc
27/11/2023	21:01	PR Newswire (US)	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders	NASDAQ:FHTX	Foghorn Therapeutics Inc
21/11/2023	08:00	PR Newswire (US)	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics	NASDAQ:FHTX	Foghorn Therapeutics Inc
01/11/2023	11:30	PR Newswire (US)	Flagship Pioneering Launches Pioneering Intelligence	NASDAQ:FHTX	Foghorn Therapeutics Inc
11/09/2023	07:30	PR Newswire (US)	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer	NASDAQ:FHTX	Foghorn Therapeutics Inc
05/09/2023	09:00	GlobeNewswire Inc.	Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences	NASDAQ:FHTX	Foghorn Therapeutics Inc
31/08/2023	08:00	GlobeNewswire Inc.	Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML	NASDAQ:FHTX	Foghorn Therapeutics Inc
29/08/2023	10:00	PR Newswire (US)	Invaio achieves first registration for citrus greening solution featuring Trecise™ technology	NASDAQ:FHTX	Foghorn Therapeutics Inc
08/08/2023	08:00	GlobeNewswire Inc.	Foghorn Therapeutics Announces Chief Medical Officer Succession	NASDAQ:FHTX	Foghorn Therapeutics Inc
04/08/2023	08:00	GlobeNewswire Inc.	Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update	NASDAQ:FHTX	Foghorn Therapeutics Inc
28/06/2023	08:06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:FHTX	Foghorn Therapeutics Inc
28/06/2023	08:00	GlobeNewswire Inc.	Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma	NASDAQ:FHTX	Foghorn Therapeutics Inc
05/06/2023	09:07	Dow Jones News	Foghorn Therapeutics Shares Rally Premarket as FDA Lifts Clinical Hold	NASDAQ:FHTX	Foghorn Therapeutics Inc
16/05/2023	07:00	PR Newswire (US)	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry	NASDAQ:FHTX	Foghorn Therapeutics Inc
08/05/2023	08:07	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:FHTX	Foghorn Therapeutics Inc
08/05/2023	08:06	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:FHTX	Foghorn Therapeutics Inc
28/04/2023	17:07	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:FHTX	Foghorn Therapeutics Inc
28/04/2023	17:01	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:FHTX	Foghorn Therapeutics Inc
22/02/2023	18:23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:FHTX	Foghorn Therapeutics Inc
09/02/2023	13:02	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:FHTX	Foghorn Therapeutics Inc
21/11/2022	13:35	TipRanks	Morgan Stanley Keeps Their Hold Rating on Foghorn Therapeutics (FHTX)	NASDAQ:FHTX	Foghorn Therapeutics Inc
09/11/2022	08:25	TipRanks	H.C. Wainwright Sticks to Its Buy Rating for Foghorn Therapeutics (FHTX)	NASDAQ:FHTX	Foghorn Therapeutics Inc
31/10/2022	17:02	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:FHTX	Foghorn Therapeutics Inc